サマリー

アジア太平洋地域のG-CSF/PEG-G-CSF市場は、2023年から2030年の予測期間に6.3%の大幅なCAGRを記録すると予測されます。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年であり、予測期間は2023年から2030年です。
市場セグメンテーションを行います：
アジア太平洋地域のG-CSF/PEG-G-CSF市場、適応症別（好中球減少症、腫瘍、慢性・自己免疫疾患、血液疾患、成長調和不全、その他）、投与量（単剤、配合剤）、投与経路（静脈内、皮下）、包装（単剤バイアル、充填済みシリンジ）、エンドユーザー（病院、診療所．研究・学術機関、外来手術センター、その他）、流通チャネル（病院薬局、オンライン薬局、小売薬局、その他）、国（中国、日本、インド、オーストラリア、ニュージーランド、インドネシア、タイ、ベトナム、シンガポール、フィリピン、マレーシア、アジア太平洋地域以外） 産業動向と2030年までの予測

アジア太平洋地域のG-CSF/PEG-G-CSF市場の成長に寄与する主な要因として、以下のものが挙げられます：

- 血液のがんやがん疾患の増加
- 発熱性好中球減少症の増加例
市場のプレーヤー：

アジア太平洋地域のG-CSF/PEG-G-CSF市場で活動している主要な市場関係者は以下の通りです：
- ルパン
- ジェノバ・バイオファーマシューティカルズ・リミテッド
- リライアンス・ライフサイエンス
- インタス・ファーマシューティカルズ・リミテッド（Intas Pharmaceuticals Ltd.
- バイオシダス
- STADA Arzneimittel AG
- USVプライベート・リミテッド
- ヴィアトリス社
- バイオコン
- フレゼニウス・カビAG
- 杭州久遠遺伝子工程有限公司（Hangzhou Jiuyuan Gene Engineering Co.
- アムジェン社
- ファイザー株式会社
- サンド・インターナショナルGmbH
- アポテックス・インク
- カディラ・ファーマシューティカルズ
- ドクターレディーズラボラトリーズLtd.
- アムニール・ファーマシューティカルズLLC
- アコードヘルスケア
- ナップ・ファーマシューティカルズ・リミテッド
- インタス・ファーマシューティカルズ・リミテッド
- ムンディファーマ・インターナショナル
- テバ・ファーマシューティカル・インダストリーズ社
- スペクトラム・ファーマシューティカルズ・インク
- 協和キリン(株)
- 江蘇恒瑞医薬有限公司

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 50
1.1 OBJECTIVES OF THE STUDY 50
1.2 MARKET DEFINITION 50
1.3 OVERVIEW OF ASIA PACIFIC G-CSF / PEG-G-CSF MARKET 50
1.4 LIMITATIONS 52
1.5 MARKETS COVERED 52
2 MARKET SEGMENTATION 55
2.1 MARKETS COVERED 55
2.2 GEOGRAPHICAL SCOPE 56
2.3 YEARS CONSIDERED FOR THE STUDY 57
2.4 CURRENCY AND PRICING 57
2.5 DBMR TRIPOD DATA VALIDATION MODEL 58
2.6 MULTIVARIATE MODELLING 61
2.7 TYPE LIFELINE CURVE 61
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 62
2.9 DBMR MARKET POSITION GRID 63
2.10 MARKET END USER COVERAGE GRID 64
2.11 VENDOR SHARE ANALYSIS 65
2.12 SECONDARY SOURCES 66
2.13 ASSUMPTIONS 66
3 EXECUTIVE SUMMARY 67
4 PREMIUM INSIGHTS 70
4.1 PESTEL ANALYSIS 71
4.2 PORTER’S FIVE FORCES 72
4.3 ASIA PACIFIC G-CSF/PEG-G-CSF MARKET: MERGERS AND ACQUISITION 73
4.4 ASIA PACIFIC G-CSF / PEG-G-CSF MARKET 74
4.5 STRATEGIES TO THE ENTER THE MARKET 74
4.5.1 JOINT VENTURE (PARTNERSHIPS): 74
4.5.2 ACQUISITION: 74
4.5.3 LINE EXPANSION VIA COLLABORATION: 74
4.5.4 PRODUCT APPROVAL: 75
4.5.5 PRODUCT LAUNCH: 75
4.5.6 GEOGRAPHIC EXPANSION: 75
4.5.7 COST LEADERSHIP: 76
4.5.8 PRODUCT DEVELOPMENT: 76
4.6 ASIA PACIFIC G-CSF / PEG-G-CSF MARKET, INDUSTRY INSIGHTS 77
4.6.1 PATENT ANALYSIS 77
4.6.2 DRUG TREATMENT RATE BY MATURED MARKETS 78
4.6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 78
4.6.4 THERAPEUTIC ASSESSMENT 78
4.6.5 KEY PRICING STRATEGIES 79
4.6.6 KEY PATIENT ENROLLMENT STRATEGIES 79
4.6.7 CONCLUSION 79
4.7 PIPELINE ANALYSIS FOR ASIA PACIFIC G-CSF / PEG-G-CSF MARKET 80
5 EPIDEMIOLOGY 81
6 ASIA PACIFIC G-CSF / PEG-G-CSF MARKET: REGULATIONS 84
7 MARKET OVERVIEW 87
7.1 DRIVERS 89
7.1.1 GROWING INCIDENCES OF BLOOD CANCERS AND CANCER DISEASES 89
7.1.2 RISING INCIDENCES OF AUTOIMMUNE DISORDERS 90
7.1.3 INCREASING CASES OF FEBRILE NEUTROPENIA 91
7.1.4 INCREASING AWARENESS ABOUT FILGRASTIM AND PEGFILGRASTIM 92
7.2 RESTRAIN 93
7.2.1 STRINGENT GOVERNMENTAL REGULATIONS 93
7.2.2 AVAILABILITY OF ALTERNATIVES FOR THE CHEMOTHERAPY 94
7.3 OPPORTUNITIES 95
7.3.1 THE USE OF BIOSIMILARS HELPS REDUCE HEALTHCARE COSTS FOR PATIENTS 95
7.3.2 COST-EFFECTIVENESS AND PATENT EXPIRY OF BIOLOGICAL PRODUCTS 95
7.4 CHALLENGES 96
7.4.1 THE HIGH COST ASSOCIATED WITH BRANDED BIOLOGICS AND IMPROVED CHEMOTHERAPY 96
7.4.2 THE MULTIPLE SIDE EFFECTS OF G-CSF 96
8 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET, BY INDICATION 97
8.1 OVERVIEW 98
8.2 NEUTROPENIA 102
8.2.1 CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (MYELOSUPPRESSIVE CHEMOTHERAPY TREATMENT) 103
8.2.2 SEVERE CHRONIC NEUTROPENIA 103
8.2.3 RADIOTHERAPY INDUCED NEUTROPENIA 103
8.2.4 NEUTROPENIA IN HIV PATIENTS 103
8.2.5 CLOZAPINE INDUCED NEUTROPENIA 103
8.2.6 NEUTROPENIA IN HEPATITIS C PATIENTS 103
8.2.7 CONGENITAL NEUTROPENIA 103
8.3 ONCOLOGY 104
8.3.1 ACUTE MYELOID LEUKEMIA RECEIVING CONSOLIDATION CHEMOTHERAPY 104
8.3.2 OTHERS 105
8.4 CHRONIC AND AUTO IMMUNE DISEASES 105
8.5 BLOOD DISORDERS 105
8.6 GROWTH HORMONE DEFICIENCY 106
8.7 OTHERS 107
9 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET, BY DOSAGE 108
9.1 OVERVIEW 109
9.2 MONO 112
9.3 COMBINATION 113
10 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION 114
10.1 OVERVIEW 115
10.2 SUBCUTANEOUS 118
10.3 INTRAVENOUS 119
11 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET, BY PACKAGING 120
11.1 OVERVIEW 121
11.2 PRE FILLED SYRINGES 124
11.3 SINGLE USE VIALS 125
12 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET, BY END USER 126
12.1 OVERVIEW 127
12.2 HOSPITALS AND CLINICS 130
12.3 RESEARCH & ACADEMIC INSTITUTES 130
12.4 AMBULATORY SURGICAL CENTERS 131
12.5 OTHERS 132
13 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL 133
13.1 OVERVIEW 134
13.2 HOSPITALS PHARMACY 137
13.3 RETAIL PHARMACY 137
13.4 ONLINE PHARMACY 138
13.5 OTHERS 139
14 ASIA PACIFIC G-CSF/PEG-G-CSF MARKET, BY REGION 140
14.1 ASIA-PACIFIC 141
14.1.1 CHINA 148
14.1.2 INDIA 156
14.1.3 INDONESIA 166
14.1.4 THAILAND 174
14.1.5 VIETNAM 181
14.1.6 SINGAPORE 188
14.1.7 PHILIPPINES 196
14.1.8 MALAYSIA 203
15 ASIA PACIFIC G-CSF / PEG-G-CSF MARKET, COMPANY LANDSCAPE 209
15.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 209
16 SWOT ANALYSIS 210
17 COMPANY PROFILE 211
17.1 PFIZER INC. 211
17.1.1 COMPANY SNAPSHOT 211
17.1.2 REVENUE ANALYSIS 212
17.1.3 COMPANY SHARE ANALYSIS 212
17.1.4 PRODUCT PORTFOLIO 213
17.1.5 RECENT DEVELOPMENTS 213
17.2 VIATRIS INC. 214
17.2.1 COMPANY SNAPSHOT 214
17.2.2 REVENUE ANALYSIS 214
17.2.3 COMPANY SHARE ANALYSIS 215
17.2.4 PRODUCT PORTFOLIO 215
17.2.5 RECENT DEVELOPMENT 215
17.3 AMGEN INC. 216
17.3.1 COMPANY SNAPSHOT 216
17.3.2 REVENUE ANALYSIS 216
17.3.3 COMPANY SHARE ANALYSIS 217
17.3.4 PRODUCT PORTFOLIO 217
17.3.5 RECENT DEVELOPMENTS 217
17.4 STADA ARZENEIMITTEL AG 219
17.4.1 COMPANY SNAPSHOT 219
17.4.2 COMPANY SHARE ANALYSIS 219
17.4.3 PRODUCT PORTFOLIO 220
17.4.4 RECENT DEVELOPMENT 220
17.5 TEVA PHARMACEUTICAL INDUSTRIES LTD. 221
17.5.1 COMPANY SNAPSHOT 221
17.5.2 REVENUE ANALYSIS 221
17.5.3 COMPANY SHARE ANALYSIS 222
17.5.4 PRODUCT PORTFOLIO 222
17.5.5 RECENT DEVELOPMENTS 222
17.6 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. 223
17.6.1 COMPANY SNAPSHOT 223
17.6.2 PRODUCT PORTFOLIO 223
17.6.3 RECENT DEVELOPMENTS 223
17.7 ACCORD HEALTHCARE 224
17.7.1 COMPANY SNAPSHOT 224
17.7.2 PRODUCT PORTFOLIO 224
17.7.3 RECENT DEVELOPMENTS 224
17.8 AMNEAL PHARMACEUTICALS LLC. 225
17.8.1 COMPANY SNAPSHOT 225
17.8.2 REVENUE ANALYSIS 225
17.8.3 PRODUCT PORTFOLIO 226
17.8.4 RECENT DEVELOPMENTS 226
17.9 APOTEX INC. 227
17.9.1 COMPANY SNAPSHOT 227
17.9.2 PRODUCT PORTFOLIO 227
17.9.3 RECENT DEVELOPMENT 227
17.10 BIOCON 228
17.10.1 COMPANY SNAPSHOT 228
17.10.2 REVENUE ANALYSIS 228
17.10.3 PRODUCT PORTFOLIO 229
17.10.4 RECENT DEVELOPMENT 229
17.11 BIO SIDUS 230
17.11.1 COMPANY SNAPSHOT 230
17.11.2 PRODUCT PORTFOLIO 230
17.11.3 RECENT DEVELOPMENTS 230
17.12 CADILA PHARMACEUTICALS 231
17.12.1 COMPANY SNAPSHOT 231
17.12.2 PRODUCT PORTFOLIO 231
17.12.3 RECENT DEVELOPMENTS 231
17.13 COHERUS BIOSCIENCES 232
17.13.1 COMPANY SNAPSHOT 232
17.13.2 REVENUE ANALYSIS 232
17.13.3 PRODUCT PORTFOLIO 233
17.13.4 RECENT DEVELOPMENT 233
17.14 DR. REDDY’S LABORATORIES LTD 234
17.14.1 COMPANY SNAPSHOT 234
17.14.2 REVENUE ANALYSIS 234
17.14.3 PRODUCT PORTFOLIO 235
17.14.4 RECENT DEVELOPMENTS 235
17.15 FRESENIUS KABI AG 236
17.15.1 COMPANY SNAPSHOT 236
17.15.2 PRODUCT PORTFOLIO 236
17.15.3 RECENT DEVELOPMENT 236
17.16 GENNOVA BIOPHARMACEUTICALS LIMITED 237
17.16.1 COMPANY SNAPSHOT 237
17.16.2 PRODUCT PORTFOLIO 237
17.16.3 RECENT DEVELOPMENTS 237
17.17 HANGZHOU JIUYUAN GENE ENGINEERING CO., LTD. 238
17.17.1 COMPANY SNAPSHOT 238
17.17.2 PRODUCT PORTFOLIO 238
17.17.3 RECENT DEVELOPMENTS 238
17.18 INTAS PHARMACEUTICALS LTD. 239
17.18.1 COMPANY SNAPSHOT 239
17.18.2 PRODUCT PORTFOLIO 239
17.18.3 RECENT DEVELOPMENT 239
17.19 KASHIV BIOSCIENCES, LLC. 240
17.19.1 COMPANY SNAPSHOT 240
17.19.2 PRODUCT PORTFOLIO 240
17.19.3 RECENT DEVELOPMENT 240
17.20 KYOWA KIRIN CO., LTD. 241
17.20.1 COMPANY SNAPSHOT 241
17.20.2 REVENUE ANALYSIS 241
17.20.3 PRODUCT PORTFOLIO 242
17.20.4 RECENT DEVELOPMENT 242
17.21 LUPIN 243
17.21.1 COMPANY SNAPSHOT 243
17.21.2 REVENUE ANALYSIS 243
17.21.3 PRODUCT PORTFOLIO 244
17.21.4 RECENT DEVELOPMENT 244
17.22 MUNDIPHARMA INTERNATIONAL. 245
17.22.1 COMPANY SNAPSHOT 245
17.22.2 PRODUCT PORTFOLIO 245
17.22.3 RECENT DEVELOPMENT 245
17.23 NAPP PHARMACEUTICALS LIMITED 246
17.23.1 COMPANY SNAPSHOT 246
17.23.2 PRODUCT PORTFOLIO 246
17.23.3 RECENT DEVELOPMENT 246
17.24 RELIANCE LIFE SCIENCES 247
17.24.1 COMPANY SNAPSHOT 247
17.24.2 PRODUCT PORTFOLIO 247
17.24.3 RECENT DEVELOPMENTS 247
17.25 SANDOZ INTERNATIONAL GMBH 248
17.25.1 COMPANY SNAPSHOT 248
17.25.2 REVENUE ANALYSIS 248
17.25.3 PRODUCT PORTFOLIO 249
17.25.4 RECENT DEVELOPMENTS 249
17.26 SPECTRUM PHARMACEUTICALS, INC. 250
17.26.1 COMPANY SNAPSHOT 250
17.26.2 PRODUCT PORTFOLIO 250
17.26.3 RECENT DEVELOPMENT 250
17.27 USV PRIVATE LIMITED 251
17.27.1 COMPANY SNAPSHOT 251
17.27.2 PRODUCT PORTFOLIO 251
17.27.3 RECENT DEVELOPMENTS 251
18 QUESTIONNAIRE 252
19 RELATED REPORTS 255

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 BELOW ARE THE RULES AND REGULATIONS TO GET APPROVAL FOR USE IN THE MARKET: 60
TABLE 2 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 77
TABLE 3 ASIA PACIFIC NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 78
TABLE 4 ASIA PACIFIC NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 78
TABLE 5 ASIA PACIFIC ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 80
TABLE 6 ASIA PACIFIC ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 80
TABLE 7 ASIA PACIFIC CHRONIC AND AUTO IMMUNE DISEASES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 81
TABLE 8 ASIA PACIFIC BLOOD DISORDERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 82
TABLE 9 ASIA PACIFIC GROWTH HORMONE DEFICIENCY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 82
TABLE 10 ASIA PACIFIC OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 83
TABLE 11 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET, BY DOSAGE, 2020-2029 (USD MILLION) 87
TABLE 12 ASIA PACIFIC MONO IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 88
TABLE 13 ASIA PACIFIC COMBINATION IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 89
TABLE 14 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 93
TABLE 15 ASIA PACIFIC SUBCUTANEOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 94
TABLE 16 ASIA PACIFIC INTRAVENOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 95
TABLE 17 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET, BY PACKAGING, 2020-2029 (USD MILLION) 99
TABLE 18 ASIA PACIFIC PRE FILLED SYRINGES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 100
TABLE 19 ASIA PACIFIC SINGLE USE VIALS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 101
TABLE 20 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET, BY END USER, 2020-2029 (USD MILLION) 105
TABLE 21 ASIA PACIFIC HOSPITALS AND CLINICS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 106
TABLE 22 ASIA PACIFIC RESEARCH & ACADEMIC INSTITUTES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 107
TABLE 23 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION) 107
TABLE 24 ASIA PACIFIC OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 108
TABLE 25 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 112
TABLE 26 ASIA PACIFIC HOSPITALS PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 113
TABLE 27 ASIA PACIFIC RETAIL PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 114
TABLE 28 ASIA PACIFIC ONLINE PHARMACY IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION) 114
TABLE 29 ASIA PACIFIC OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 115
TABLE 30 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION) 120
TABLE 31 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION) 120
TABLE 32 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY COUNTRY, 2020-2030 (USD MILLION) 120
TABLE 33 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 121
TABLE 34 ASIA-PACIFIC NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 121
TABLE 35 ASIA-PACIFIC ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 121
TABLE 36 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 122
TABLE 37 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 122
TABLE 38 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 122
TABLE 39 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 122
TABLE 40 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 123
TABLE 41 CHINA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 124
TABLE 42 CHINA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 124
TABLE 43 CHINA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 125
TABLE 44 CHINA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 125
TABLE 45 CHINA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 125
TABLE 46 CHINA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 125
TABLE 47 CHINA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 126
TABLE 48 CHINA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 126
TABLE 49 CHINA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 126
TABLE 50 CHINA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 127
TABLE 51 CHINA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 127
TABLE 52 CHINA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 127
TABLE 53 CHINA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 128
TABLE 54 CHINA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 128
TABLE 55 CHINA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 128
TABLE 56 CHINA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 128
TABLE 57 CHINA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 128
TABLE 58 CHINA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 129
TABLE 59 CHINA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 129
TABLE 60 CHINA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 129
TABLE 61 CHINA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 129
TABLE 62 CHINA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 130
TABLE 63 CHINA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 130
TABLE 64 CHINA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 130
TABLE 65 CHINA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 130
TABLE 66 CHINA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 131
TABLE 67 CHINA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 131
TABLE 68 INDIA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 132
TABLE 69 INDIA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 132
TABLE 70 INDIA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 133
TABLE 71 INDIA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 133
TABLE 72 INDIA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 133
TABLE 73 INDIA COMBINATION IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 133
TABLE 74 INDIA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 134
TABLE 75 INDIA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 134
TABLE 76 INDIA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 134
TABLE 77 INDIA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 134
TABLE 78 INDIA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 135
TABLE 79 INDIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 135
TABLE 80 INDIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 135
TABLE 81 INDIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 136
TABLE 82 INDIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 136
TABLE 83 INDIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 136
TABLE 84 INDIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 137
TABLE 85 INDIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 137
TABLE 86 INDIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 137
TABLE 87 INDIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 138
TABLE 88 INDIA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 138
TABLE 89 INDIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 138
TABLE 90 INDIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 139
TABLE 91 INDIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 139
TABLE 92 INDIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 139
TABLE 93 INDIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 140
TABLE 94 INDIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 140
TABLE 95 INDIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 140
TABLE 96 INDIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 141
TABLE 97 INDIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 141
TABLE 98 INDONESIA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 142
TABLE 99 INDONESIA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 142
TABLE 100 INDONESIA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 143
TABLE 101 INDONESIA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 143
TABLE 102 INDONESIA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 143
TABLE 103 INDONESIA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 143
TABLE 104 INDONESIA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 144
TABLE 105 INDONESIA INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 144
TABLE 106 INDONESIA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 144
TABLE 107 INDONESIA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 144
TABLE 108 INDONESIA SINGLE USE VIALS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 145
TABLE 109 INDONESIA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 145
TABLE 110 INDONESIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 145
TABLE 111 INDONESIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 145
TABLE 112 INDONESIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 146
TABLE 113 INDONESIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 146
TABLE 114 INDONESIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 146
TABLE 115 INDONESIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 146
TABLE 116 INDONESIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 146
TABLE 117 INDONESIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 147
TABLE 118 INDONESIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 147
TABLE 119 INDONESIA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 147
TABLE 120 INDONESIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 147
TABLE 121 INDONESIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 148
TABLE 122 INDONESIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 148
TABLE 123 INDONESIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 148
TABLE 124 INDONESIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 148
TABLE 125 INDONESIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 148
TABLE 126 INDONESIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 148
TABLE 127 INDONESIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 149
TABLE 128 INDONESIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 149
TABLE 129 THAILAND G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 150
TABLE 130 THAILAND NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 150
TABLE 131 THAILAND ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 151
TABLE 132 THAILAND G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 151
TABLE 133 THAILAND MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 151
TABLE 134 THAILAND G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 151
TABLE 135 THAILAND SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 152
TABLE 136 THAILAND G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 152
TABLE 137 THAILAND PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 152
TABLE 138 THAILAND G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 152
TABLE 139 THAILAND HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 153
TABLE 140 THAILAND HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 153
TABLE 141 THAILAND HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 153
TABLE 142 THAILAND RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 153
TABLE 143 THAILAND RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 153
TABLE 144 THAILAND RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 154
TABLE 145 THAILAND AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 154
TABLE 146 THAILAND AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 154
TABLE 147 THAILAND AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 154
TABLE 148 THAILAND G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 154
TABLE 149 THAILAND HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 155